Affimed (NASDAQ:AFMD) stock is on the move Friday as investors prepare for the clinical-stage biopharmaceutical company’s shares to undergo a reverse split later today. AFMD stock will go through a one-for-10 reverse stock split after markets close today. That will result in the company’s shares starting to trade on a split-adjusted basis when markets open on Monday. Shareholders approved of this reverse stock split during the company’s on June 21, 2023. It’s also worth mentioning that this split won’t allo ...

I’m about to drop a truth bomb about speculative stocks under $1. Back when I was a freshman in college, the on-campus security officer had this to say: “Tijuana? You don’t wanna.” Subsequently, the crowd erupted in laughter but the officer got his point across. Yes, Tijuana is an exciting and vibrant city, no doubt about it. However, people – especially young underage college students – can get carried away. That’s the reality behind speculative stocks under $1. It’s like Tijuana, where the same restrictio ...

股票合并 - 公司计划进行1比10的股票合并，以符合纳斯达克上市要求[1] - 股票合并预计在2024年3月8日收盘后生效，股票将在2024年3月11日以新的交易符号“AFMD”在纳斯达克资本市场上交易[2] - 股东持有的股票将不会发行零头股份，而是将获得现金支付以取代零头股份[2] - 股东在2023年6月21日的股东大会上批准了股票合并，旨在使公司符合纳斯达克继续上市的最低每股1美元的要求[3] 公司产品和研发 - 公司的ICE®分子在临床开发中，作为单药或联合疗法进行研究，总部位于德国曼海姆，由一支经验丰富的生物技术和制药领导团队领导[5] - 公司的前瞻性声明包括对公司意图、信念、展望、分析和当前期望的陈述，涉及公司的产品候选者、ROCK®平台的价值、合作关系、临床试验等方面[6]

o o o ¢ Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohort Follow-up shows three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still awaiting a confirmatory scan Study to be expanded to a total of 40 EGFRwt NSCLC patients Enrollment in the EGFR-mutant (mut) NSCLC cohort is ongoing Data from both the EGFRwt and EGFRmut cohorts expected in H1 2024 o M ...

MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definitive agreement to sell its wholly- owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines. Under the terms of the agreement, Ampersand Biomedicines will acquire AbCheck for a purchase price of $6 million, consisting of $5 million in cash to ...

Affimed N.V. (NASDAQ:AFMD) Q3 2023 Results Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Alexander Fudukidis - Director and Head of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Conference Call Participants Srikripa Devarakonda - Truist Securities Li Watsek - Cantor Fitzgerald Daina Graybosch - Leerink Partners Yanan Zhu - Wells Fargo Bradley Canino ...

HARNESSING THE UNTAPPED POTENTIAL OF THE INNATE IMMUNE SYSTEM FOR ONCOLOGY Q3 2023 Financial Results & Operational Progress NASDAQ: AFMD November 14, 2023 Forward-Looking Statements / Cautionary Note 2 This presentation and the accompanying oral commentary contain "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral commentary, including statements regarding our future ...

Affimed N.V. (NASDAQ:AFMD) Q2 2023 Earnings Call Transcript August 10, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Arndt Schottelius - Chief Scientific Officer Conference Call Participants Maurice Raycroft - Jefferies Daina Graybosch - Leverink Partners Li Watsek - Cantor Fitzgerald Yale Jen - Laidlaw & Co Yana ...

Affimed N.V. (NASDAQ:AFMD) Q1 2023 Earnings Conference Call May 23, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Arndt Schottelius - Chief Scientific Officer Conference Call Participants Maurice Raycroft - Jefferies Li Watsek - Cantor Fitzgerald Srikripa Devarakonda - Truist Securities Bradley Canino - Stifel Ya ...

Exhibit 99.1 Affimed N.V. Unaudited consolidated statements of comprehensive loss (in € thousand) | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------|-------|-------------------------------------------|-----------------| | | Note | For the three months March \n2023 | ended 31 \n2022 | | Revenue | 3 | 4,510 | 8,006 | | Other income – net | | 410 | 284 | | Research and development expenses | | (29,531) | (18,379) | | General and administra ...